-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMP-9064 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMP-9064 in Solid Tumor Drug Details: IMP-9064 is under development for the treatment of ATM...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMP-7068 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMP-7068 in Colorectal Cancer Drug Details:IMP-7068 is under development for the treatment of  advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMP-7068 in Uterine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IMP-7068 in Uterine Cancer Drug Details:IMP-7068 is under development for the treatment of  advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMP-731 in Plaque Psoriasis (Psoriasis Vulgaris)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IMP-731 in Plaque Psoriasis (Psoriasis Vulgaris)Drug Details:GSK-2831781 is under development for the treatment of ulcerative colitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Senaparib + Temozolomide) in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Senaparib + Temozolomide) in Small-Cell Lung Cancer Drug Details:Senaparib (IMP-4297) in combination with temozolomide (TMZ)Â is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Senaparib + Temozolomide) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Senaparib + Temozolomide) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:Senaparib (IMP-4297) in combination with temozolomide...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Senaparib + Temozolomide) in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Senaparib + Temozolomide) in Triple-Negative Breast Cancer (TNBC) Drug Details:Senaparib (IMP-4297) in combination with temozolomide (TMZ)Â is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Senaparib + Temozolomide) in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Senaparib + Temozolomide) in Solid Tumor Drug Details:Senaparib (IMP-4297) in combination with temozolomide (TMZ)Â is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Senaparib + Temozolomide) in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Senaparib + Temozolomide) in Ovarian Cancer Drug Details:Senaparib (IMP-4297) in combination with temozolomide (TMZ)Â is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: Eftilagimod alfa (IMP-321,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.